Kuehl A K, Noormohamed S E
Department of Preventive Medicine, College of Medicine, University of Iowa, Iowa City 52242, USA.
Ann Pharmacother. 1995 Jul-Aug;29(7-8):778-9. doi: 10.1177/106002809502907-821.
Recombinant erythropoietin (Epogen, Amgen Pharmaceuticals; Procrit, Amgen Pharmaceuticals, distributed by Ortho Biotech) is approved for use in anemia associated with HIV infection and treatment. The recommended starting dose is 100 IU/kg iv or sc 3 times per week. Current evidence suggests that anemia in zidovudine-treated patients may be a result of insufficient quantities of erythropoietin, bone marrow unresponsiveness to the hormone, or HIV infection. Among patients receiving zidovudine, a review of the available data suggests that baseline serum erythropoietin concentrations may aid in predicting the response to exogenous hormone administration.
